Haijun Gu
Shanghai Key Laboratory Of Regulatory Biology
Shanghai, 200241, China
Shanghai, 200241, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Discovery of a Highly Potent and Selective MYOF Inhibitor with Improved Water Solubility for the Treatment of Gastric Cancer.
Journal: Journal of medicinal chemistry
Published: December 06, 2023
Discovery of Pyrimidinediamine Derivatives as Potent Methuosis Inducers for the Treatment of Triple-Negative Breast Cancer.
Journal: Journal of medicinal chemistry
Published: May 22, 2023
Current advances of small molecule E3 ligands for proteolysis-targeting chimeras design.
Journal: European journal of medicinal chemistry
Published: March 29, 2023
B-cell Lymphoma 6 Inhibitors: Current Advances and Prospects of Drug Development for Diffuse Large B-cell Lymphomas.
Journal: Journal of medicinal chemistry
Published: November 28, 2022
Discovery of 1,5-diaryl-1,2,4-triazole derivatives as myoferlin inhibitors and their antitumor effects in pancreatic cancer.
Journal: Future medicinal chemistry
Published: September 27, 2022
Discovery of a Novel Potent STAT3 Inhibitor HP590 with Dual p-Tyr705/Ser727 Inhibitory Activity for Gastric Cancer Treatment.
Journal: Journal of medicinal chemistry
Published: September 14, 2022
A potent and selective small molecule inhibitor of myoferlin attenuates colorectal cancer progression.
Journal: Clinical and translational medicine
Published: September 30, 2020
An Emerging Therapeutic Approach by Targeting Myoferlin (MYOF) for Malignant Tumors.
Journal: Current topics in medicinal chemistry
Published: June 11, 2020
Synthesis and Biological Evaluation of B-Cell Lymphoma 6 Inhibitors of N-Phenyl-4-pyrimidinamine Derivatives Bearing Potent Activities against Tumor Growth.
Journal: Journal of medicinal chemistry
Published: January 03, 2020
Showing 1-9 of 9
Last Updated: 09/26/2026